STOCKS TELEGRAPH

Tag: Sonnet

  • Sonnet (SONN) Shares Surge on News of Transformational Business Deal

    Sonnet (SONN) Shares Surge on News of Transformational Business Deal

    Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares were surging 152.22% as of the last check in early trading today, reaching $13.04, following the announcement of a transformative business combination agreement.

    SONN revealed it has entered into a definitive Business Combination Agreement (BCA) with Rorschach I LLC and associated sponsors, setting the stage for a strategic shift in its corporate focus.

    Formation of Hyperliquid Strategies Inc. and Strategic Holdings

    Rorschach I LLC is a newly established entity affiliated with Atlas Merchant Capital LLC and Paradigm Operations LP. Through this agreement, Sonnet BioTherapeutics aims to reposition its business by creating a substantial reserve of HYPE—the token native to the Hyperliquid Layer-1 blockchain.

    The combined company will be known as Hyperliquid Strategies Inc. (HSI) after the deal closes. It is anticipated that it will have roughly 12.6 million HYPE tokens, which are worth about $583 million, along with $305 million in gross cash investments, for a total assumed closing value of $888 million.

    Notable Participation of Investors and Appointments to Leadership

    The deal is being backed by a number of renowned investors, including Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital. As a publicly traded cryptocurrency treasury company, HSI is expected to stay listed on the Nasdaq Capital Market with a new ticker symbol.

    Alongside the purchase, there will be changes in leadership: David Schamis, co-founder and CIO of Atlas, will be named CEO, and Bob Diamond, co-founder and CEO of Atlas, will be appointed Chairman. In addition, two of Sonnet BioTherapeutics’ current independent directors and former Boston Federal Reserve President Eric Rosengren will join the board.

    Private Placement and Biotech Development Continuation

    Sonnet BioTherapeutics will raise $5.5 million as part of the deal by issuing warrants and non-voting convertible preferred shares through a private placement. At the end of the placement, convertible notes worth $2.0 million that were issued in June 2025 will also convert. Along with expenses related to the company combination, the proceeds will be used to fund working capital, ongoing biotech development, and general corporate operations.

    With this deal, Sonnet BioTherapeutics is able to retain investing in its core biotech portfolio while taking advantage of prospects in the digital asset sector, marking a significant strategic shift for the firm.

  • Sonnet (SONN) Gains Momentum Following Encouraging Trial Results

    Sonnet (SONN) Gains Momentum Following Encouraging Trial Results

    After the release of encouraging topline safety results from the Phase 1 SB101 clinical study of SON-1010, shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) saw a notable increase on the US stock charts today. As of the last check during current session, SONN stock was surging 49.33% to $3.14.

    Promoting Results in Advanced Solid Tumor Research

    In significant Phase-1 research, Sonnet evaluated SON-1010 (IL12-FHAB), its proprietary recombinant human interleukin-12 (rhIL-12) fusion protein, in adult patients with advanced solid tumors. The trial, which has so far included 24 participants, aims to assess the drug’s safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD). Minimal toxicity was verified by the Safety Review Committee’s review at the highest dose, which is encouraging considering the past difficulties with rhIL-12.

    SON-1010 targets the tumor microenvironment (TME) and improves its half-life and bioactivity by utilizing Sonnet’s Fully Human Albumin Binding (FHAB) technology. This innovative design facilitates binding to gp60 and Secreted Protein Acidic and Rich in Cysteine (SPARC), ensuring effective delivery to tumor sites.

    Advancing Toward Therapeutic Potential

    The trial results indicate that SON-1010 achieves robust yet controlled IFNγ responses, critical for antitumor activity, with a sustained return to baseline levels. Notably, a partial response (PR) observed at the highest dose highlights the drug’s potential to synergize with checkpoint inhibitors or chemotherapy. Nearly half of the evaluable patients demonstrated clinical benefits, marking a significant step toward realizing rhIL-12’s long-anticipated therapeutic promise.

    Strategic Plans for Future Development

    With dose escalation successfully completed, Sonnet has established the maximum tolerated dose (MTD) for SON-1010. The company continues to monitor treated patients for long-term safety and tumor responses while actively seeking partnerships to advance the drug into later-stage development.

    Together with atezolizumab, SON-1010 is being assessed in a Phase 1b/2a dose-escalation and proof-of-concept study (SB221) for platinum-resistant ovarian cancer (PROC) in partnership with Genentech, a Roche Group member. An update on safety at the MTD in that trial is anticipated in Q1 2025, and enrollment is still open.

    This achievement represents a pivotal moment for Sonnet BioTherapeutics, affirming its commitment to transforming cancer treatment through innovative biotechnology.

  • Sonnet BioTherapeutics (SONN) Stock Surges After Regaining Nasdaq Compliance

    Sonnet BioTherapeutics (SONN) Stock Surges After Regaining Nasdaq Compliance

    Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) has seen a significant boost in share price, with the stock rising to $6.11, or a 20.28% increase. The company’s recent declaration that it complies with Nasdaq listing standards is the reason for this spike.

    Sonnet Regained Nasdaq Compliance

    The Nasdaq Stock Market LLC formally notified Sonnet on October 16, 2024, that it had once again complied with the bid price threshold required for the company to be listed on the Nasdaq. This encouraging development has helped SONN’s stock price rise, indicating investor confidence in the company’s strategic path.

    SONN Inked Strategic Licensing Agreement

    As a further indication of its potential for expansion, Sonnet recently signed a license deal with Alkem Laboratories Limited. The research, development, production, marketing, and commercialization of Sonnet’s patented drug, SON-080, for the treatment of diabetic peripheral neuropathy (DPN) in India are the main objectives of this partnership.

    Under the terms of this partnership, Alkem is set to provide Sonnet with an initial payment of $1 million, along with potential milestone payments that could total an additional $1 million. Furthermore, Sonnet will receive royalties calculated as a low double-digit percentage of the net sales of SON-080 upon its commercialization in India, excluding certain expenses outlined in the licensing agreement.

    Advancing Clinical Development And Market Opportunities

    With this collaboration, Sonnet aims to advance SON-080 into Phase 2 clinical development. The data generated from Alkem’s planned Phase 2 study will facilitate the establishment of additional partnerships in key markets, thereby providing critical therapeutic options for patients suffering from DPN—a condition that presents a significant unmet medical need in the healthcare landscape.

    Positive outcomes from Sonnet’s ongoing clinical trial’s finished Phase 1b segment have also surfaced, emphasizing SON-080’s well-tolerated profile and potential for quick symptom relief in CIPN patients. These findings will help the company maintain a competitive edge in the pharmaceutical industry.